Semax + Selank Cognitive Stack

They act through complementary mechanisms: Semax increases BDNF, enhances catecholamine signaling, and promotes focus and verbal fluency. Selank modulates GABA-A receptors and enkephalin metabolism, reducing anxiety without sedation. The combination addresses both the 'drive' and 'calm' dimensions of cognitive performance.

Yes — the peptides have no known interactions with racetams, modafinil, caffeine, or standard nootropic supplements. Their mechanism (neurotrophic + GABAergic) is distinct from most synthetic nootropics.

Semax has acute effects within 15–30 minutes of intranasal dosing (improved focus, verbal fluency). Selank's anxiolytic effects also onset within 30–60 minutes. Full neurotrophic benefits (BDNF upregulation) develop over days to weeks of consistent use.

Standard protocols cycle 2–4 weeks on, 1–2 weeks off. However, Russian clinical practice has reported daily use for months without tolerance or withdrawal. The cycling is precautionary rather than evidence-mandated. If cognitive benefits fade during a cycle, a break followed by resumption typically restores responsiveness.

NA-Selank Amidate has N-acetyl and C-amide modifications that improve metabolic stability and receptor binding. Users generally report stronger and longer-lasting anxiolytic effects per dose. However, no comparative clinical trials exist — the preference is based on pharmacokinetic reasoning and anecdotal reports. Start with standard selank if new to the stack.

Dihexa (N-hexanoic-Tyr-Ile-(6)aminohexanoic amide) is a potent HGF/c-Met pathway activator studied for synaptogenesis and memory. Adding it to the Semax + Selank stack creates a triple-mechanism approach: BDNF (Semax) + GABA modulation (Selank) + HGF-driven synaptogenesis (Dihexa). The combination is mechanistically coherent but adds a compound with very limited human safety data — Dihexa is a pure research peptide. Most practitioners start with the Semax + Selank base before considering additions.

Semax and Selank are individually approved medications in Russia, each with published clinical data. However, no controlled trial has tested the combination vs. either peptide alone. The combination rationale is based on complementary pharmacology — not direct comparative evidence. Russian clinical practice routinely uses both, but this reflects medical tradition rather than RCT-level evidence for the combination specifically.